Novartis voluntarily halts price increases; Shkreli's former company considers name change; FDA issues guidance to modernize electronic health data in trials.
J&J beats expectations on Q2 earnings; AbbVie, Mylan sign U.S. license deal for Humira; Roche's new flu drug meets endpoints.
MM&M Awards shortlist revealed; FDA approves first smallpox treatment; Another way Amazon could drive down healthcare costs.
Senate probe finds more contact between Novartis, Cohen; J&J ordered to pay $4.7 billion in talc lawsuit; FDA warns Arog about misleading promotional material.
Pfizer announces restructuring hours after about face on price hikes; Feds to slash funding for ACA "navigators"; Study finds rural states lag in combating heart disease.
CMS ends plan to make Novartis cancer treatment cheaper; Trump calls out Pfizer on Twitter for price hikes; News organizations sue to get federal opioid data.
The most comprehensive look at the pharma and healthcare agency world from MM&M.
Positive Alzheimer's trial sends Biogen shares surging; A year after crisis, analysts come around to AstraZeneca stock; Ironwood cuts 40 jobs ahead of split.
Amazon integration with PillPack could happen quickly; White House names DEA chief; Purdue stops marketing opioids in Canada.
UDG Healthcare makes two acquisitions; Lundbeck names Dunsire CEO; Accuracy of DTC genetic tests questioned.
U.S. hospitals face staple drug shortage; Pfizer hikes price of 100 products; Federal judge blocks Kentucky work-requirement-for-Medicaid plan.
Fosamax appeal goes to Supreme Court; Gottlieb weighs in on Amazon-PillPack deal; Senator demands PhRMA, BIO address sexual harassment.
FDA gives priority review to new type of flu treatment; Lynparza shows positive trial data; Nurse practitioner lobby launches national campaign.
FDA approves first prescription drug derived from marijuana; Alphabet aging unit raises $1 billion; GE to spin off healthcare business.
How Atul Gawande caught Warren Buffett's eye; Positive news for Roche's Tecentriq in trial; New York State officials argue Orkambi not worth the cost.
Opioid supply levels drop; Azar criticized for attending college reunion during border crisis; CVS CEO confident about Aetna deal.
GoodRx in sales talks; Heron receives breakthrough therapy designation for pain treatment; Novo's diabetes pill proves effective in clinical trials.
Dr. Atul Gawande named CEO of Amazon, J.P. Morgan, Berkshire Hathaway healthcare venture; Facebook tries to curb illegal opioid sales; More sales layoffs at Purdue Pharma.
White House to roll out Affordable Care Act rule change; CVS Health teams up with Postal Service; Roche to buy rest of Foundation Medicine.
Quest Analytics buys BetterDoctor; Analyst Eric Schmidt to join Allogene Therapeutics; Two-thirds of Americans "very concerned" about cost of health insurance.
Eli Lilly CEO says changes needed in drug pricing system; Kentucky sues Walgreens over opioid epidemic; Teva faces migraine drug setback.
BIO afterparty again sparks controversy; GSK meets goal for two-drug HIV treatment; Mylan receives complete response letter for Advair generic.
Drugmakers not dropping prices on Trump timeline; Azar backs insurance for those with preexisting conditions; Stryker denies interest in Boston Scientific takeover.
FDA puts Sage depression treatment on accelerated timeline; AstraZeneca, Lilly cease Alzheimer's treatment trial; Stryker makes offer for Boston Scientific.
Eckert returns to lead Sprout Pharmaceuticals; Sorrell denies prostitution allegation; AHIP warns about removing key Obamacare provisions.
Novo Nordisk considers cutting 3,000 jobs; Pharma companies pressured to move birth control over the counter; Gates Foundation launches a nonprofit biotech.
Bayer closes Monsanto deal after lengthy antitrust review; Bezos, Dimon, Buffett pick CEO to run healthcare venture; Novartis to avoid criminal actions over Cohen payments.
Athenahealth CEO steps down; Former Celgene chief executive wins New Jersey Senate primary; Big Pharma not planning campaign against Trump drug pricing plan.
Medicare Part D brand-name drug costs up even as prescriptions fall; Gottlieb could speed up approval process for competitors of first-to-market drugs; FDA approves Filphila.
Opioid prescriptions drop for fifth year in a row; AstraZeneca reprimanded by U.K. regulator; Samsung partners with Babylon to bring appointments to smartphones.